羟苯磺酸钙胶囊联合丹参注射液治疗老年2型糖尿病早期视网膜病变的临床疗效  

Clinical trial of calcium dobesilate capsules combined with Danshen injection in the treatment of elderly patients with early diabetic retinopathy

作　　者：姜丽萍[1] 庄晓林[1] 吴庆峰[1] 富强[1] 王宏伟[2] 

机构地区：[1]齐齐哈尔医学院第一附属医院眼科,黑龙江齐齐哈尔160141 [2]靖江市人民医院眼科,江苏靖江214500

出　　处：《中国临床药理学杂志》2017年第14期1304-1306,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(81170856)

摘　　要：目的观察羟苯磺酸钙胶囊联合丹参注射液治疗老年2型糖尿病早期视网膜病变的临床疗效及安全性。方法将58例老年2型糖尿病早期视网膜病变患者随机分为对照组29例和试验组29例。对照组予以羟苯磺酸钙每次0.5g,tid,口服;试验组在对照组治疗的基础上,予以丹参注射液20 mL,qd,静脉滴注,治疗2周停药1周。2组患者均治疗3个月。比较2组患者的临床疗效、血管内皮细胞生长因子(VEGF)、胰岛素样生长因子1(IGF-1)、超敏C-反应蛋白(hs-CRP)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为93.10%(27/29例)和72.41%(21/29例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的血清VEGF分别为(82.32±9.73)和(105.24±10.05)pg·mL^(-1),IGF-1分别为(89.66±8.79)和(124.24±9.86)ng·mL^(-1),hs-CRP分别为(3.98±0.52)和(6.76±0.83)mg·L^(-1),差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有面部潮红和恶心呕吐,对照组的药物不良反应主要有恶心呕吐和食欲缺乏。试验组和对照组的药物不良反应发生率分别为10.34%和6.90%,差异无统计学意义(P>0.05)。结论羟苯磺酸钙胶囊联合丹参注射液治疗老年2型糖尿病早期视网膜病变的临床疗效显著,其能够明显降低患者的血清VEGF、IGF-1及hs-CRP水平,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of cal- cium dobesilate capsules combined with Danshen injection in the treat- ment of elderly patients with early diabetic retinopathy. Methods A to- tal of 58 elderly patients with early diabetic retinopathy were randomly di- vided into the control group and treatment group with 29 cases per group. Control group was given calcium dobesilate 0. 5 g, tid, oral. Treatment group was treated with Danshen injection 20 mL, qd, intravenous drip, on the basis of the control group. Two groups were treated for 3 months. The clinical efficacy, serum levels of vascular endothelial growth factor （VEGF）, insulin - like growth factor 1 （ IGF - 1 ） and high sensitive C - reactive protein （hs -CRP）, adverse drug reactions were compared between two groups. Results After treatment, the total effective rates in treatment and control groups were 93. ,10% （27/29 cases） and 72.41% （21/29 cases） with statistically significant difference （ P 〈 0. 05 ）. After treatment, the main indexes in treatment and control groups were compared： VEGF were （82. 32 ± 9.73 ）, （105.24±10.05）pg· mL-1; IGF-1 were （89.66 ±8.79）, （124.24 ±9.86）ng· mL-1; hs-CRP were （3.98 ±0. 52）, （6. 76 ~0. 83）mg · L^-1, the differences were statistically significant （P 〈0. 05）. The adverse drug reactions in treatment group were based on facial flushing, nausea and vomiting, which in control group were nausea and vomiting, lack of appetite. The incidences of adverse drug reaction in treatment and control groups were 10. 34% and 6. 90% without significant difference （P 〉 0. 05）. Conclusion Calcium dobesilate capsules combined with Dan- shen injection have a definitive clinical efficacy in the treatment of elderly patients with early diabetic retinopathy, which can significantly reduce the patients＇ serum levels of VEGF, IGF - 1 and hs - CRP, without increasing the incidence of adverse drug reactions.

关 键 词：羟苯磺酸钙胶囊 丹参注射液 2型糖尿病早期视网膜病变 安全性 

分 类 号：R988.1[医药卫生—药品]